|1.||Gatot, Jean-Stéphane: 1 article (07/2012)|
|2.||Kabeya, Kabamba: 1 article (07/2012)|
|3.||Rohr, Olivier: 1 article (07/2012)|
|4.||Van Lint, Carine: 1 article (07/2012)|
|5.||Clumeck, Nathan: 1 article (07/2012)|
|6.||Colin, Laurence: 1 article (07/2012)|
|7.||Herbein, Georges: 1 article (07/2012)|
|8.||Bouchat, Sophie: 1 article (07/2012)|
|9.||De Wit, Stéphane: 1 article (07/2012)|
|10.||Rouzioux, Christine: 1 article (07/2012)|
10/31/2009 - "To our knowledge, the HMTI-Fc antibody shown here is the smallest fully functional antibody and may have a potential for treatment of cancer."
07/31/2012 - "Moreover, we showed that combinatory treatments including one HMTI and either the histone deacetylase inhibitor suberoylanilide hydroxamic acid or the non-tumor-promoting NF-κB inducer prostratin had a higher reactivation potential than these compounds alone. "
|2.||Colorectal Neoplasms (Colorectal Cancer)
01/03/1995 - "Analysis of SFCM of subclones with different histological differentiation and metastatic/invasive potentials derived from a single pancreatic carcinoma cell line SUIT-2 showed that the HMTI activity in SFCM was correlated to the degree of histological differentiation in vivo and tended to be inversely correlated to their metastatic/invasive capabilities. "
|1.||Histone Deacetylase Inhibitors
|3.||vorinostat (suberoylanilide hydroxamic acid)